GlassScriptPhysician profile
Alejandra Staubs
NPI 1013302561
$2,821.05
in general payments reported to CMS, 2019-2025
25 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $222 · 2021: $463 · 2022: $712 · 2023: $848 · 2024: $298 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,423.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $731.77 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $324.23 | 2020-2025 | Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $254.29 | 2021-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $243.25 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $177.73 | 2020-2024 | Breztri |
| Amarin Pharma, INC. | $132.89 | 2021-2022 | |
| Bausch Health US, LLC | $122.83 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.60 | 2022-2024 | Trulance, Xifaxan |
| Pfizer INC. | $101.53 | 2023-2025 | |
| Amgen INC. | $93.22 | 2023-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $70.46 | 2021-2023 | Rexulti |
| Shield Therapeutics INC | $64.32 | 2022-2023 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.14 | 2021-2023 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.34 | 2022-2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $41.89 | 2024 | Gvoke Hypopen |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $38.49 | 2023-2025 | Veozah, Myrbetriq |
| Azurity Pharmaceuticals, INC. | $35.39 | 2023 | Horizant |
| Sanofi-Aventis U.S. LLC | $28.16 | 2021-2022 | |
| Abbott Laboratories | $25.59 | 2022 | |
| Vapotherm INC | $21.44 | 2022 | |
| Janssen Pharmaceuticals, INC | $21.35 | 2023 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $19.56 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.97 | 2024 | |
| Supernus Pharmaceuticals, INC. | $13.39 | 2024 | Qelbree |
| Genentech USA, INC. | $11.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandra Staubs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.